ATLASense Biomed

Company Overview

Snapshot

Founded in June 2015 by Tal Or, ATLASense Biomed operates with 11–50 employees. The company has secured $2.81M in total capital across six funding rounds. In February 2025, ATLASense Biomed unveiled its REPHAEL platform, signaling a new era in remote health monitoring.

Business overview

ATLASense Biomed develops a wearable solution for clinical decision support, addressing the challenge of safely and cost-effectively transitioning healthcare from hospitals to homes. Its core product, REPHAEL, is a wearable platform designed for ICU-level monitoring and predictive insights, capable of detecting and alerting healthcare teams to critical risks such as respiratory failure, sepsis, heart failure, and falls days before they escalate. The company serves the healthcare industry, enabling remote, informed clinical decisions and providing hospital-level care at home through continuous, comprehensive monitoring powered by proprietary sensors and AI-driven insights. ATLASense Biomed operates within the Health Tech & Life Sciences sector, specifically focusing on Digital Healthcare and Patient Remote Monitoring.

Strategic signal

In February 2025, ATLASense Biomed launched its REPHAEL platform, a significant development in remote health monitoring. This platform offers ICU-level monitoring and predictive insights, aiming to revolutionize how care is delivered outside traditional hospital settings. This launch signals the company's commitment to advancing home-based care solutions and leveraging AI and wearable technology to prevent critical health events, positioning it as a key player in the evolving digital healthcare landscape.

Company Intelligence Q&A

What is the primary focus of ATLASense Biomed's REPHAEL platform?

The REPHAEL platform by ATLASense Biomed focuses on delivering ICU-level monitoring and predictive insights through a wearable solution, enabling safe and cost-effective healthcare transitions from hospitals to homes. It predicts, detects, and alerts healthcare teams to critical risks like respiratory failure, sepsis, heart failure, and falls.

When did ATLASense Biomed unveil its REPHAEL platform?

ATLASense Biomed unveiled its REPHAEL platform in February 2025, marking a new era in remote health monitoring.

What recognition did ATLASense Biomed receive in March 2020?

In March 2020, ATLASense Biomed earned the Henry Ford Health System's Global Health Tech Challenge Top Prize for its patient monitoring system.

What is ATLASense Biomed's total capital raised to date?

ATLASense Biomed has raised a total of $2.81 million across six funding rounds.

Who is the founder of ATLASense Biomed?

ATLASense Biomed was founded by Tal Or.